Quarterly report · Q1
2160.TEDINET S100QRIK
Period2023-01-01 → 2023-03-31
Filed2023-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.2bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥17.4bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥3.9bn | 2022-01-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Operating income | ¥398m | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥479m | 2022-01-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥65m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥768m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥347m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥3m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥389m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥351m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥342m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥868m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥72m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥34.1bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥33.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥32.6bn | at 2022-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥14.3bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥14.1bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥19.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥20.5bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.3bn | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥21.2bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥20.3bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥10.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.0bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.8bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.4bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥710m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥393m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥426m | 2022-01-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥1.2bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥4.1bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥298m | 2022-01-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥52m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥646m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥331m | 2022-01-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-0.06 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥8.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥7.4 | 2022-01-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-0.06 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥8.11 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥7.36 | 2022-01-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 62.2% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.8% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.4% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥23m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥623m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥600m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥23m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥248m |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥3.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥3.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥149m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥4.2bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥4.2bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥23m |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | ¥398m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥532m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥532m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | segment profit | 2022-01-01 → 2022-03-31 | ¥255m |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥3.4bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥3.4bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | segment profit | 2022-01-01 → 2022-03-31 | ¥224m |
| —segment total | revenue | 2022-01-01 → 2022-03-31 | ¥3.9bn |
| —segment total | revenue external | 2022-01-01 → 2022-03-31 | ¥3.9bn |
| —segment total | segment profit | 2022-01-01 → 2022-03-31 | ¥479m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 547
| Item | Context | Value | Unit |
|---|---|---|---|
| Total transactions with owners IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | 32195000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | － | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration | 32195000 | JPY |
| Equity IFRS | CurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember | 21205560000 | JPY |
| Equity IFRS | CurrentQuarterInstant_NonControllingInterestsIFRSMember | -1419429000 | JPY |
| Equity IFRS | CurrentQuarterInstant | 19786131000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 347425000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | -64934000 | JPY |
| Depreciation expense ope cf IFRS | Prior1YTDDuration | 115034000 | JPY |
| Depreciation expense ope cf IFRS | CurrentYTDDuration | 136501000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | -390520000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | 634319000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | -5778000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -355840000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -47536000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | 14720000 | JPY |
| Bonus allowance ope cf IFRS | Prior1YTDDuration | 2127000 | JPY |
| Bonus allowance ope cf IFRS | CurrentYTDDuration | 6167000 | JPY |
| Finance income and finance costs ope cf IFRS | Prior1YTDDuration | 174349000 | JPY |
| Finance income and finance costs ope cf IFRS | CurrentYTDDuration | 190440000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | 335441000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | 420397000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 530542000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 981771000 | JPY |
| Interest received ope cf IFRS | Prior1YTDDuration | 12351000 | JPY |
| Interest received ope cf IFRS | CurrentYTDDuration | 22066000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -7169000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -5516000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -110096000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -288361000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 425628000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 709959000 | JPY |
| Net decrease increase in time deposits inv cf IFRS | Prior1YTDDuration | － | JPY |
| Net decrease increase in time deposits inv cf IFRS | CurrentYTDDuration | -771072000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -71314000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -267660000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -228248000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -198631000 | JPY |
| Increase of rent deposit inv cf IFRS | Prior1YTDDuration | -253000 | JPY |
| Increase of rent deposit inv cf IFRS | CurrentYTDDuration | -3599000 | JPY |
| Decrease of rent deposit inv cf IFRS | Prior1YTDDuration | 428000 | JPY |
| Decrease of rent deposit inv cf IFRS | CurrentYTDDuration | － | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YTDDuration | 1185000 | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYTDDuration | 1185000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -298202000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -1239778000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YTDDuration | -300000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYTDDuration | － | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -25274000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -51798000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |